Drug developers continue to raise significant venture capital in 2015 with experienced executives and novel therapeutic approaches attracting large VC funding rounds to support early-stage research and development programs, including a $40m Series C round for True North Therapeutics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?